ArticleTherapeutic drug monitoring2025
Precision Dosing of Meropenem in a Neonate on CARPEDIEM Dialysis: A Grand Round.
Article in Therapeutic drug monitoring, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antimicrobial pharmacokinetics in pediatric patients on kidney replacement therapy: a comprehensive narrative review.Pediatric nephrology (Berlin, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOptimal antibiotic dosing is challenging in critically ill neonates because of the substantial pharmacokinetic variability, which is influenced by factors such as immature renal function, body composition, and critical illness. The use of extracorporeal therapies adds complexity, making predictions difficult in many cases. Meropenem, a broad-spectrum antibiotic, is commonly used due to resistant gram-negative organisms in neonates; however, dosing guidelines for neonates on CARPEDIEM dialysis are lacking.
methodsThis is a case of a neonate with liver failure of unclear etiology, who was on CARPEDIEM dialysis and started on meropenem for sepsis due to extended-spectrum beta-lactamase-producing Escherichia coli and suspected meningitis. Blood samples were sent to an external laboratory for meropenem concentration measurements, and model-informed precision dosing was used to guide the dosing adjustments.
resultsInitially, meropenem was administered at 40 mg/kg every 8 hours with a 30-min infusion, resulting in exposures that exceeded those required to achieve free concentrations above 4 times the minimum inhibitory concentration for the entire dosing interval (100% f T >4xMIC). The dosing interval was adjusted to every 12 hours to avoid unnecessarily high exposure. The regimen was continued without further complications, and the patient underwent successful liver transplantation.
conclusionsThis case highlights the successful application of model-informed precision dosing to individualize meropenem therapy in a critically ill neonate with liver failure on CARPEDIEM dialysis. MIPD is a valuable tool for dose adjustment in patients with unique and unpredictable pharmacokinetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.